使用围产期细胞的先进细胞疗法临床试验的第一个十年（2005 - 2015年）。
The first decade of advanced cell therapy clinical trials using perinatal cells (2005-2015).
作者信息
Couto Pedro S, Bersenev Alexey, Verter Frances
机构信息
Parent's Guide to Cord Blood Foundation, Brookeville, MD 20833, USA.
Cell Therapy Laboratory at Yale-New Haven Hospital, Yale University, CT 06520, USA.
出版信息
Regen Med. 2017 Dec;12(8):953-968. doi: 10.2217/rme-2017-0066. Epub 2017 Nov 15.
AIM
The first review of advanced cell therapy trials with perinatal cells.
MATERIALS & METHODS: We compiled 281 clinical trials of advanced cell therapy with perinatal cells that were registered in 2005-2015.
RESULTS
The most common cell source in these trials is cord blood, but the cell type that provides the mechanism of action in the majority of trials is mesenchymal stem/stromal cells. We analyze trends among the 15 parameters we compiled for these trials.
CONCLUSION
Advanced cell therapy with perinatal cells is a new field that covers a wide range of diagnoses but where most of the trials are early Phase. Researchers in different countries tend to work with a preferred cell source and cell type.
目的
首次对围产期细胞的先进细胞疗法试验进行综述。
材料与方法
我们汇总了2005年至2015年期间注册的281项围产期细胞先进细胞疗法临床试验。
结果
这些试验中最常见的细胞来源是脐带血，但在大多数试验中提供作用机制的细胞类型是间充质干/基质细胞。我们分析了为这些试验汇总的15个参数的趋势。
结论
围产期细胞的先进细胞疗法是一个新领域，涵盖广泛的诊断，但大多数试验处于早期阶段。不同国家的研究人员倾向于使用首选的细胞来源和细胞类型。
Zotero 插件